A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...
Keay Nakae’s rating is based on Avidity Biosciences’ strategic focus on genetically validated targets for cardiomyopathies using their proprietary antibody oligonucleotide conjugate (AOC) technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback